SCHEMBL3660255

SCHEMBL3660255

O=C(O)C(CC1CCC1)c1cc(Cl)c(OCC(F)(F)F)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 4/20 1.00
PSEN2 P49810 4/20 1.00
APH1B Q8WW43 4/20 1.00
NCSTN Q92542 4/20 1.00
APH1A Q96BI3 4/20 1.00
PSENEN Q9NZ42 4/20 1.00
APP P05067 3/20 1.00
AKR1C3 P42330 3/20 0.39
AKR1C2 P52895 3/20 0.39
THRB P10828 1/20 0.39
FFAR4 Q5NUL3 2/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.36
KCNH2 Q12809 2/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
BDKRB1 P46663 1/20 0.35
CNR1 P21554 2/20 0.34
MGLL Q99685 1/20 0.34
FABP4 P15090 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3660252 1.00 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3713834 1.00 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL29549427 1.00 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3656191 0.96 PSEN1 (0.93) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3656190 0.96 PSEN1 (0.93) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3656189 0.96 PSEN1 (0.93) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3654547 0.92 APP (0.84) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3658905 0.92 APP (0.84) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3654545 0.92 APP (0.84) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL16284109 0.91 PSEN1 (0.83) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234954-B1 TETRASUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS INC (US) 2015-02-18 EP claimed
US-20140364641-A1 Tetrasubstituted Benzenes ENVIVO PHARMACEUTICALS, INC. (US) 2014-12-11 US claimed
WO-2014159814-A1 FORMULATIONS AND TABLETS FOR TREATMENT OR PREVENTION OF NEUROLOGICAL DISORDERS OLIVER PATRICIA (US) 2014-10-02 WO claimed
WO-2014159811-A1 SALTS AND POLYMORPHS OF A COMPOUND OLIVER PATRICIA (US) 2014-10-02 WO claimed
US-8367863-B2 Tetrasubstituted benzenes ENVIVO PHARMACEUTICALS, INC. (US) 2013-02-05 US claimed
US-20120295981-A1 TETRASUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS, INC. (US) 2012-11-22 US claimed
US-8217064-B2 Tetrasubstituted benzenes ENVIVO PHARMACEUTICALS, INC. (US) 2012-07-10 US claimed
EP-2234954-B1 TETRASUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS INC (US) 2015-02-18 EP disclosed
EP-2234954-B1 TETRASUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS INC (US) 2015-02-18 EP disclosed
US-20140364641-A1 Tetrasubstituted Benzenes ENVIVO PHARMACEUTICALS, INC. (US) 2014-12-11 US disclosed
US-20140364641-A1 Tetrasubstituted Benzenes ENVIVO PHARMACEUTICALS, INC. (US) 2014-12-11 US disclosed
WO-2014159811-A1 SALTS AND POLYMORPHS OF A COMPOUND OLIVER PATRICIA (US) 2014-10-02 WO disclosed
WO-2014159811-A1 SALTS AND POLYMORPHS OF A COMPOUND OLIVER PATRICIA (US) 2014-10-02 WO disclosed
US-8217064-B2 Tetrasubstituted benzenes ENVIVO PHARMACEUTICALS, INC. (US) 2012-07-10 US disclosed
EP-2234954-A1 TETRASUBSTITUTED BENZENES Envivo Pharmaceuticals, Inc. (US) 2010-10-06 EP disclosed
US-20090299072-A1 Tetrasubstituted Benzenes EN VIVO PHARMACEUTICALS, INC. 2009-12-03 US disclosed
US-20090299072-A1 Tetrasubstituted Benzenes EN VIVO PHARMACEUTICALS, INC. 2009-12-03 US disclosed
US-20090299072-A1 Tetrasubstituted Benzenes EN VIVO PHARMACEUTICALS, INC. 2009-12-03 US disclosed
WO-2009086277-A1 TETRASUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS, INC. (US) 2009-07-09 WO disclosed
WO-2009086277-A1 TETRASUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364641-A1 Tetrasubstituted Benzenes BACE1, BACE2, PSEN1 PSEN1 3/4885PSEN2 4/4885APH1B 7/4885
US-20090299072-A1 Tetrasubstituted Benzenes BACE1, BACE2, PSEN1 PSEN1 3/4885PSEN2 4/4885APH1B 7/4885
US-20120295981-A1 TETRASUBSTITUTED BENZENES BACE1, BACE2, PSEN1 PSEN1 3/4885PSEN2 4/4885APH1B 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.